Kun Liu

7PUBLICATIONS
8CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 19, 2026
The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis.

|Jan 01, 2026
International Cost-Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced-Stage Classic Hodgkin's Lymphoma.

Youwen Zhu, Kun Liu, Steven T Rosen

|Jul 07, 2025
International cost-effectiveness analysis of chemoradiotherapy plus pembrolizumab for locally advanced cervical cancer.

Kun Liu, Youwen Zhu, Hong Zhu

|Jan 08, 2025
Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis.

Youwen Zhu, Kun Liu, Hong Zhu

|Jun 10, 2024
Immunotherapy plus chemotherapy in patients with advanced endometrial cancer: a cost-effectiveness analysis.

Youwen Zhu, Kun Liu, Hong Zhu

|Apr 05, 2024
Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis.

Youwen Zhu, Yinxin Lin, Kun Liu

Pageof 2

Frequent Collaborators

7 joint publications

Youwen Zhu

6 joint publications

Hong Zhu

1 joint publications

Qiuping Yang

1 joint publications

Hui Cao